LGALS1 and primary cutaneous T-cell non-Hodgkin lymphoma: Exogenous administration of galectin-1 affects the viability, proliferation, and Th17 and Th1 responses of non-malignant T cells involved in the progression of cutaneous T-cell lymphoma (36). In homeostasis, Lgals1−/− mice develop normally and do not exhibit any evident alteration compared to galectin-1 sufficient mice (37).